Advertisement

The Effect of Positive Surgical Margins After Thyroidectomy on Patient Prognosis in Cases with Differentiated Thyroid Carcinoma

  • Gülin Uçmak
  • Burcu Esen Akkaş
Chapter

Abstract

The presence of gross/macroscopic positive margins and incomplete resection has long been recognized as significant risk factors for disease recurrence in patients with differentiated thyroid carcinoma (DTC). However, this is less clear for patients with microscopic positive margin when other significant risk factors are not present. In this chapter, two cases are presented in order to discuss the impact of microscopically involved surgical margins on disease recurrence.

Keywords

Surgical margins Differentiated thyroid cancer Prognosis 

References

  1. 1.
    Haugen BR, Alexander EK, Bible KC, Doherty GM, Mandel SJ, Nikiforov YE, et al. 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American Thyroid Association guidelines task force on thyroid nodules and differentiated thyroid cancer. Thyroid. 2016;26:1–133.CrossRefGoogle Scholar
  2. 2.
    Pacini F, Schlumberger M, Dralle H, Elisei R, Smit JW, Wiersinga W. European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. Eur J Endocrinol. 2006;154:787–803.CrossRefGoogle Scholar
  3. 3.
    Mazzaferri EL, Kloos RT. Clinical review 128: current approaches to primary therapy for papillary and follicular thyroid cancer. J Clin Endocrinol Metab. 2001;86:1447–63.CrossRefGoogle Scholar
  4. 4.
    Mazzaferri EL, Jhiang SM. Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. Am J Med. 1994;97:418–28.CrossRefGoogle Scholar
  5. 5.
    Komorowski RA, Hanson GA. Occult thyroid pathology in the young adult: an autopsy study of 138 patients without clinical thyroid disease. Hum Pathol. 1988;19:689–96.CrossRefGoogle Scholar
  6. 6.
    Lang BH, Shek TW, Wan KY. Does microscopically involved margin increase disease recurrence after curative surgery in papillary thyroid carcinoma? J Surg Oncol. 2016;113:635–9.  https://doi.org/10.1002/jso.2419.CrossRefPubMedGoogle Scholar
  7. 7.
    Kluijfhout WP, Pasternak JD, Kwon JS, Lim J, Shen WT, Gosnell JE, et al. Microscopic positive tumor margin does not increase the risk of recurrence in patients with T1-T2 well-differentiated thyroid cancer. Ann Surg Oncol. 2016;23:1446–51.  https://doi.org/10.1245/s10434-015-4998-x.CrossRefPubMedGoogle Scholar
  8. 8.
    Seethala RR, Asa SL, Carty SE, Hodak SP, McHugh JB, Richardson MS, et al. College of American Pathologist. Protocol for the examination of specimens from patients with carcinomas of the thyroid gland. 2017. http://www.cap.org/ShowProperty?nodePath=/UCMCon/Contribution%20Folders/WebContent/pdf/cp-thyroid-17protocol-4000.pdf. Accessed 28 June 2017.
  9. 9.
    Vural GU, Akkas BE, Ercakmak N, Basu S, Alavi A. Prognostic significance of FDG PET/CT on the follow-up of patients of differentiated thyroid carcinoma with negative 131I whole-body scan and elevated thyroglobulin levels: correlation with clinical and histopathologic characteristics and long-term follow-up data. Clin Nucl Med. 2012;37:953–9.  https://doi.org/10.1097/RLU.0b013e31825b2057.CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Bachelot A, Cailleux AF, Klain M, Baudin E, Ricard M, Bellon N, et al. Relationship between tumor burden and serum thyroglobulin level in patients with papillary and follicular thyroid carcinoma. Thyroid. 2002;12:707–11.CrossRefGoogle Scholar
  11. 11.
    Giovanella L, Ceriani L, Ghelfo A, Maffioli M, Keller F. Preoperative undetectable serum thyroglobulin in differentiated thyroid carcinoma: incidence, causes and management strategy. Clin Endocrinol. 2007;67:547.Google Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2019

Authors and Affiliations

  • Gülin Uçmak
    • 1
  • Burcu Esen Akkaş
    • 1
  1. 1.Department of Nuclear MedicineUniversity of Health Sciences (SBÜ) Dr. Abdurrahman Yurtaslan Ankara Oncology Training and Research HospitalAnkaraTurkey

Personalised recommendations